The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Ovarian Low-grade and High-grade Serous Carcinoma: Pathogenesis, Clinicopathologic and Molecular Biologic Features, and Diagnostic Problems
Open accessAbstract
Ovarian serous carcinomas have been graded using various systems. Recently, a 2-tier system in which tumors are subdivided into low grade and high grade has been proposed. This approach is simplistic, reproducible, and based on biologic evidence indicating that both tumors develop via different pathways. Low-grade serous carcinomas exhibit low-grade nuclei with infrequent mitotic figures. They evolve from adenofibromas or borderline tumors, have frequent mutations of the KRAS, BRAF, or ERBB2 genes, and lack TP53 mutations (Type I pathway). The progression to invasive carcinoma is a slow step-wise process. Low-grade tumors are indolent and have better outcome than high-grade tumors. In contrast, high-grade serous carcinomas have high-grade nuclei and numerous mitotic figures. Identification of a precursor lesion in the ovary has been elusive and therefore the origin of ovarian carcinoma has been described as de novo. More recently, studies have suggested that a proportion seem to originate from intraepithelial carcinoma in the fallopian tube. The development of these tumors is rapid (Type II pathway). Most are characterized by TP53 mutations and lack mutations of KRAS, BRAF, or ERBB2. Although both types of serous carcinomas evolve along different pathways, rare high-grade serous carcinomas seem to arise through the Type I pathway. Immunohistochemical stains for p53, p16, and Ki-67 for distinction of low-grade from high-grade tumors are of limited value but can be helpful in selected instances. This review provides an update on the pathogenesis and clinicopathologic features of these 2 types of serous carcinomas and addresses some of the diagnostic problems that are encountered in routine practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rubin, M., & Stephen, C. D. (1993) · Cited by 3,149
Shih, I.-M., & Kurman, R. J. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63708-x · Cited by 1,206
Self-citationKindelberger, D. W., Lee, Y., Miron, A., Hirsch, M. S., Feltmate, C., Medeiros, F., Callahan, M. J., Garner, E. O., Gordon, R. W., Birch, C., et al. (2007) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213335.40358.47 · Cited by 1,113
Risch, H. A., McLaughlin, J. R., Cole, D. E. C., Rosen, B., Bradley, L., Kwan, E., Jack, E., Vesprini, D. J., Kuperstein, G., Abrahamson, J. L. A., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318787 · Cited by 986
Medeiros, F., Muto, M. G., Lee, Y., Elvin, J. A., Callahan, M. J., Feltmate, C., Garber, J. E., Cramer, D. W., & Crum, C. P. (2006) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000180854.28831.77 · Cited by 916
A candidate precursor to serous carcinoma that originates in the distal fallopian tube
Lee, Y., Miron, A., Drapkin, R., Nucci, M., Medeiros, F., Saleemuddin, A., Garber, J., Birch, C., Mou, H., Gordon, R., et al. (2007) · The Journal of Pathology · doi:10.1002/path.2091 · Cited by 898
Mutations in BRAF and KRAS Characterize the Development of Low-Grade Ovarian Serous Carcinoma
Singer, G., Oldt, R., Cohen, Y., Wang, B. G., Sidransky, D., Kurman, R. J., & Shih, I.-M. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.6.484 · Cited by 854
Self-citationCho, K. R., & Shih, I.-M. (2009) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092246 · Cited by 694
Self-citationBRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases
Pal, T., Permuth‐Wey, J., Betts, J. A., Krischer, J. P., Fiorica, J., Arango, H., LaPolla, J., Hoffman, M., Martino, M. A., Wakeley, K., et al. (2005) · Cancer · doi:10.1002/cncr.21536 · Cited by 691
Grading Ovarian Serous Carcinoma Using a Two-Tier System
Malpica, A., Deavers, M. T., Lu, K., Bodurka, D. C., Atkinson, E. N., Gershenson, D. M., & Silva, E. G. (2004) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200404000-00009 · Cited by 670
Singer, G., Stöhr, R., Cope, L., Dehari, R., Hartmann, A., Cao, D.-F., Wang, T.-L., Kurman, R. J., & Shih, I.-M. (2005) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000146025.91953.8d · Cited by 408
Self-citationOrigins and molecular pathology of ovarian cancer
Bell, D. A. (2005) · Modern Pathology · doi:10.1016/s0893-3952(22)04456-8 · Cited by 387
Histopathologic Grading of Ovarian Carcinoma: A Review and Proposal
Silverberg, S. G. (2000) · International Journal of Gynecological Pathology · doi:10.1097/00004347-200001000-00003 · Cited by 351
Carlson, J. W., Miron, A., Jarboe, E. A., Parast, M. M., Hirsch, M. S., Lee, Y., Muto, M. G., Kindelberger, D., & Crum, C. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.4814 · Cited by 347
Diverse Tumorigenic Pathways in Ovarian Serous Carcinoma
Singer, G., Kurman, R. J., Chang, H.-W., Cho, S. K. R., & Shih, I.-M. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62549-7 · Cited by 340
Self-citationLongacre, T. A., McKenney, J. K., Tazelaar, H. D., Kempson, R. L., & Hendrickson, M. R. (2005) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000164030.82810.db · Cited by 323
Bonome, T., Lee, J.-Y., Park, D.-C., Radonovich, M., Pise-Masison, C., Brady, J., Gardner, G. J., Hao, K., Wong, W. H., Barrett, J. C., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2240 · Cited by 319
Burks, R. T., Sherman, M. E., & Kurman, R. J. (1996) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199611000-00003 · Cited by 314
Self-citationSantin, A. D., Zhan, F., Bellone, S., Palmieri, M., Cane, S., Bignotti, E., Anfossi, S., Gokden, M., Dunn, D., Roman, J. J., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20408 · Cited by 313
Clinical Behavior of Stage II-IV Low-Grade Serous Carcinoma of the Ovary
Gershenson, D. M., Sun, C. C., Lu, K. H., Coleman, R. L., Sood, A. K., Malpica, A., Deavers, M. T., Silva, E. G., & Bodurka, D. C. (2006) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000227787.24587.d1 · Cited by 290
Serous Carcinogenesis in the Fallopian Tube: A Descriptive Classification
Jarboe, E., Folkins, A., Nucci, M. R., Kindelberger, D., Drapkin, R., Miron, A., Lee, Y., & Crum, C. P. (2008) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e31814b191f · Cited by 273
Primary carcinoma of the Fallopian tube
Hu, C. Y., Taymor, M. L., & Hertig, A. T. (1950) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(50)90341-3 · Cited by 273
Shimizu, Y., Kamoi, S., Amada, S., Akiyama, F., & Silverberg, S. G. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980301)82:5<893::aid-cncr14>3.0.co;2-w · Cited by 254
Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum
Schmeler, K. M., Sun, C. C., Bodurka, D. C., T. Deavers, M., Malpica, A., Coleman, R. L., Ramirez, P. T., & Gershenson, D. M. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.11.013 · Cited by 245
Gilks, C. B., Ionescu, D. N., Kalloger, S. E., Köbel, M., Irving, J., Clarke, B., Santos, J., Le, N., Moravan, V., & Swenerton, K. (2008) · Human Pathology · doi:10.1016/j.humpath.2008.01.003 · Cited by 242
In ovarian neoplasms, BRAF , but not KRAS , mutations are restricted to low‐grade serous tumours
Sieben, N. L., Macropoulos, P., Roemen, G. M., Kolkman‐Uljee, S. M., Jan Fleuren, G., Houmadi, R., Diss, T., Warren, B., Al Adnani, M., de Goeij, A. P., et al. (2004) · The Journal of Pathology · doi:10.1002/path.1521 · Cited by 237
Mayr, D., Hirschmann, A., Löhrs, U., & Diebold, J. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.05.029 · Cited by 224
Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis
Reid-Nicholson, M., Iyengar, P., Hummer, A. J., Linkov, I., Asher, M., & Soslow, R. A. (2006) · Modern Pathology · doi:10.1038/modpathol.3800620 · Cited by 219
Inactivation of BRCA1 and BRCA2 in Ovarian Cancer
Hilton, J. L. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.18.1396 · Cited by 218
Mutations of BRAF and KRAS Precede the Development of Ovarian Serous Borderline Tumors
Ho, C.-L., Kurman, R. J., Dehari, R., Wang, T.-L., & Shih, I.-M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2067 · Cited by 206
Self-citationKuo, K.-T., Guan, B., Feng, Y., Mao, T.-L., Chen, X., Jinawath, N., Wang, Y., Kurman, R. J., Shih, I.-M., & Wang, T.-L. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3913 · Cited by 196
Self-citationSequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms
Nakayama, K., Nakayama, N., Kurman, R. J., Cope, L., Pohl, G., Samuels, Y., Velculescu, V. E., Wang, T.-L., & Shih, I.-M. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.7.2751 · Cited by 187
Self-citationPlante, M., Rubin, S. C., Wong, G. Y., Federici, M. G., Finstad, C. L., & Gastl, G. A. (1994) · Cancer · doi:10.1002/1097-0142(19940401)73:7<1859::aid-cncr2820730714>3.0.co;2-l · Cited by 177
O'Neill, C. J., Deavers, M. T., Malpica, A., Foster, H., & McCluggage, W. G. (2005) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000166367.68459.7d · Cited by 164
Malpica, A., Deavers, M. T., Tornos, C., Kurman, R. J., Soslow, R., Seidman, J. D., Munsell, M. F., Gaertner, E., Frishberg, D., & Silva, E. G. (2007) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31803199b0 · Cited by 159
Self-citationDehari, R., Kurman, R. J., Logani, S., & Shih, I. (2007) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31802cbbe9 · Cited by 150
Self-citationSeidman, J. D., Soslow, R. A., Vang, R., Berman, J. J., Stoler, M. H., Sherman, M. E., Oliva, E., Kajdacsy‐Balla, A., Berman, D. M., & Copeland, L. J. (2004) · Human Pathology · doi:10.1016/j.humpath.2004.03.004 · Cited by 146
Self-citationSehdev, A. E. S., Sehdev, P. S., & Kurman, R. J. (2003) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200306000-00003 · Cited by 142
Self-citationFrequency of BRCA1 Dysfunction in Ovarian Cancer
Geisler, J. P. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.1.61 · Cited by 141
Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma
Shih, I., Sheu, J. J., Santillan, A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504195102 · Cited by 138
Self-citationCharacterization of Active Mitogen-Activated Protein Kinase in Ovarian Serous Carcinomas
Hsu, C., Bristow, R. E., Cha, M. S., Wang, B. G., Ho, C., Kurman, R. J., Wang, T., & Shih, I. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0893 · Cited by 132
Self-citationNakayama, K., Nakayama, N., Davidson, B., Sheu, J. J., Jinawath, N., Santillan, A., Salani, R., Bristow, R. E., Morin, P. J., Kurman, R. J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604083103 · Cited by 131
Self-citationPohl, G., Ho, C., Kurman, R. J., Bristow, R. E., Wang, T., & Shih, I. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3625 · Cited by 123
Self-citationSalani, R., Kurman, R. J., Giuntoli, R. L., Gardner, G. J., Bristow, R. E., Wang, T., & Shih, I. (2007) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2007.01039.x · Cited by 120
Self-citationTubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective
Jarboe, E. A., Folkins, A. K., Drapkin, R., Ince, T. A., Agoston, E. S., & Crum, C. P. (2009) · Histopathology · doi:10.1111/j.1365-2559.2009.03408.x · Cited by 115
Singer, G., Shih, I., Truskinovsky, A. M., Umudum, H., & Kurman, R. J. (2003) · International Journal of Gynecological Pathology · doi:10.1097/00004347-200301000-00009 · Cited by 113
Self-citationNakayama, N., Nakayama, K., Yeasmin, S., Ishibashi, M., Katagiri, A., Iida, K., Fukumoto, M., & Miyazaki, K. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604783 · Cited by 113
McKenney, J. K., Balzer, B. L., & Longacre, T. A. (2006) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213299.11649.fa · Cited by 105
Davidson, B., Zhang, Z., Kleinberg, L., Li, M., Flørenes, V. A., Wang, T., & Shih, I. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1059 · Cited by 105
Self-citationO’Neill, C., McBride, H. A., Connolly, L. E., Deavers, M. T., Malpica, A. L., & McCluggage, W. G. (2007) · Histopathology · doi:10.1111/j.1365-2559.2007.02682.x · Cited by 98
VANG, R. S., Gown, A. M., Farinola, M. A., Barry, T. S., Wheeler, D. T., Yemelyanova, A. V., Seidman, J. D., Judson, K., & Ronnett, B. M. (2007) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213369.71676.25 · Cited by 96
Self-citationTubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective
Jarboe, E. A., Folkins, A. K., Drapkin, R., Ince, T. A., Agoston, E. S., & Crum, C. P. (2008) · Histopathology · doi:10.1111/j.1365-2559.2007.02938.x · Cited by 92
Low-grade serous ovarian cancer: a unique disease
Schmeler, K. M., & Gershenson, D. M. (2008) · Current Oncology Reports · doi:10.1007/s11912-008-0078-8 · Cited by 89
Defining the Cut Point Between Low-grade and High-grade Ovarian Serous Carcinomas
Ayhan, A., Kurman, R. J., Yemelyanova, A. V., et al. (2009) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181a24354 · Cited by 80
Self-citationShvartsman, H. S., Sun, C. C., Bodurka, D. C., Mahajan, V., Crispens, M. A., Lu, K. H., Deavers, M. T., Malpica, A. L., Silva, E. G., & Gershenson, D. M. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.01.030 · Cited by 73
Early Recurrence of Ovarian Serous Borderline Tumor as High-grade Carcinoma: A Report of Two Cases
Parker, R. L., Clement, P. B., Chercover, D. J., Sornarajah, T., & Gilks, C. B. (2004) · International Journal of Gynecological Pathology · doi:10.1097/01.pgp.0000130049.19643.f6 · Cited by 57
Armes, J. E., Lourie, R., de Silva, M., et al. (2005) · International Journal of Gynecological Pathology · doi:10.1097/01.pgp.0000172083.94934.1e · Cited by 54
Staebler, A., Heselmeyer‐Haddad, K., Bell, K. A., Riopel, M. A., Perlman, E. J., Ried, T., & Kurman, R. J. (2002) · Human Pathology · doi:10.1053/hupa.2002.30212 · Cited by 52
Self-citationVANG, R. S., Shih, I., Salani, R., Sugar, E. A., Ayhan, A., & Kurman, R. J. (2008) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31816fd555 · Cited by 46
Self-citationK-ras Mutations in Müllerian Inclusion Cysts Associated with Serous Borderline Tumors of the Ovary
Secord, A. A., MOORE, W. F., Robboy, S. J., Bentley, R. C., Gumbs, C. E., Futreal, P. A., & Berchuck, A. (2001) · Gynecologic Oncology · doi:10.1006/gyno.2000.6066 · Cited by 41
Nuclear size distinguishes low- from high-grade ovarian serous carcinoma and predicts outcome
Hsu, C., Kurman, R. J., VANG, R. S., Wang, T., Baak, J. P. A., & Shih, I. (2005) · Human Pathology · doi:10.1016/j.humpath.2005.07.014 · Cited by 38
Self-citationLow-grade Serous Carcinoma of the Ovary Displaying a Macropapillary Pattern of Invasion
Yemelyanova, A. V., Mao, T., Nakayama, N., Shih, I., & Kurman, R. J. (2008) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318181a7ce · Cited by 32
Self-citationKhalifeh, I. M., Munkarah, A. R., Lonardo, F., Malone, J. M., Morris, R. T., Lawrence, W. D., & Ali‐Fehmi, R. (2004) · International Journal of Gynecological Pathology · doi:10.1097/00004347-200404000-00011 · Cited by 31
Cited by
Evaluating cell lines as tumour models by comparison of genomic profiles
Domcke, S., Sinha, R., Levine, D. A., Sander, C., & Schultz, N. (2013) · Nature Communications · doi:10.1038/ncomms3126 · Cited by 1,418
Ledermann, J. A., Raja, F. A., Fotopoulou, C., Gonzalez-Martin, A., Colombo, N., & Sessa, C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt333 · Cited by 1,104
Ovarian cancer in the world: epidemiology and risk factors
Momenimovahed, Z., Tiznobaik, A., Taheri, S., & Salehiniya, H. (2019) · International Journal of Women's Health · doi:10.2147/ijwh.s197604 · Cited by 912
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
Ahmed, A. A., Etemadmoghadam, D., Temple, J., Lynch, A. G., Riad, M., Sharma, R., Stewart, C., Fereday, S., Caldas, C., deFazio, A., et al. (2010) · The Journal of Pathology · doi:10.1002/path.2696 · Cited by 787
PARP inhibition elicits STING-dependent antitumor immunity in brca1-deficient ovarian cancer
Ding, L., Kim, H.-J., Wang, Q., Kearns, M., Jiang, T., Ohlson, C. E., Li, B. B., Xie, S., Liu, J. F., Stover, E. H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.054 · Cited by 572
Metadata
- Authors
- Vang, R., Shih, I.-M., & Kurman, R. J.
- Venue
- Advances in Anatomic Pathology
- Published
- 2009-09
- Volume
- 16
- Issue
- 5
- Pages
- 267-282
- ISSN
- 1072-4109 (ISSN-L)
- OpenAlex
- W2053263835
- Cited by
- 562
- References
- 63
- FWCI
- 28.49
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.